Apyx Medical Corporation (NASDAQ:APYX) Given Average Recommendation of “Moderate Buy” by Analysts

Apyx Medical Corporation (NASDAQ:APYX) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $6.60.

A number of research analysts have issued reports on APYX shares. HC Wainwright initiated coverage on Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Finally, Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th.

Apyx Medical Stock Performance

Shares of APYX stock opened at $4.05 on Friday. The company has a debt-to-equity ratio of 2.68, a current ratio of 5.80 and a quick ratio of 4.79. The firm has a 50-day moving average of $4.24 and a 200-day moving average of $3.94. Apyx Medical has a one year low of $1.70 and a one year high of $5.08. The company has a market cap of $169.74 million, a P/E ratio of -20.25 and a beta of 1.39.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.18%. The business had revenue of $13.88 million for the quarter, compared to analysts’ expectations of $13.18 million. Equities research analysts forecast that Apyx Medical will post -0.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Apyx Medical

A number of hedge funds have recently modified their holdings of APYX. AIGH Capital Management LLC purchased a new stake in Apyx Medical in the second quarter worth $5,066,000. Nantahala Capital Management LLC lifted its stake in shares of Apyx Medical by 19.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after buying an additional 636,043 shares in the last quarter. BlackRock Inc. bought a new position in shares of Apyx Medical in the second quarter worth $2,519,000. Sei Investments Co. grew its holdings in Apyx Medical by 298.6% during the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after buying an additional 448,174 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new position in Apyx Medical during the fourth quarter valued at approximately $863,000. Institutional investors own 55.33% of the company’s stock.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.